Janelle Sharkey - Concepedia

Author

Janelle Sharkey

Peter MacCallum Cancer Centre

Also Known As

J A Sharkey, Janelle Sharkey

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Peter MacCallum Cancer Centre The University of Melbourne Juntendo University Beth Israel Deaconess Medical Center Monash University

About

Janelle Sharkey is an author at Peter MacCallum Cancer Centre specializing in tumor biology, immunology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	762
2	Immunology	6	6	762
3	Cell Biology	5	5	686
4	Autoimmunity	2	2	104
5	Developmental Biology	1	1	20

Janelle Sharkey

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis John Stagg, Upulie Divisekera, Nicole M. McLaughlin, Proceedings of the National Academy of Sciences Tumor ImmunologyBreast OncologyCancer ImmunosurveillanceTumor GrowthImmunology	2010	561
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis Jeremy B. Swann, Matthew D. Vesely, Anabel Silva, Proceedings of the National Academy of Sciences	2008	299
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist Ailsa J. Frew, Ralph K. Lindemann, Ben P. Martin, Proceedings of the National Academy of Sciences	2008	148
Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy. Alan W. Stitt, Jonathan E. Moore, Janelle Sharkey, PubMed	1998	139
Type I natural killer T cells suppress tumors caused by p53 loss in mice Jeremy B. Swann, Adam P. Uldrich, Serani van Dommelen, Blood	2009	110
Multiple Antitumor Mechanisms Downstream of Prophylactic Regulatory T-Cell Depletion Michele W.L. Teng, Jeremy B. Swann, Bianca von Scheidt, Cancer Research Cancer ImmunosurveillanceT-regulatory CellImmunologyTumor ImmunityTreg Depletion	2010	76
Combined Natural Killer T-Cell–Based Immunotherapy Eradicates Established Tumors in Mice Michele W.L. Teng, Jennifer A. Westwood, Phillip K. Darcy, Cancer Research	2007	68
Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize <i>in vivo</i> and induce an antitumor immune response John Stagg, Janelle Sharkey, Sandra Pommey, Proceedings of the National Academy of Sciences Breast OncologyImmunologyImmunoeditingCell DeathImmune System	2008	47
CD1d-Based Combination Therapy Eradicates Established Tumors in Mice Michele W.L. Teng, Janelle Sharkey, Nicole M. McLaughlin, The Journal of Immunology Cancer ImmunosurveillanceTumor SuppressionImmunologyTumor ImmunityImmunoediting	2009	30
Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice Jennifer A. Westwood, Phillip K. Darcy, P Guru, Journal of Translational Medicine	2010	29

Page 1